REFERENCES
- Fisher RI, Gaynor ER, Dahlberg S et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med1993;328:1002–1006.
- Haioun C, Lepage E, Gisselbrecht C et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH-87 protocol. A Groupe d'Etude des Lymphomes de l'Adulte study. J Clin Oncol 2000;18:3025–3030.
- Tilly H, Mourner N, Lederlin P et al. Randomized compar-ison of ACVBP and m-BACOD in the treatment of patients with low-risk aggressive lymphoma: The LNH 87-1 study. J C lin Oncol 2000;18:1309–1315.
- Gordon U, Harrington D, Andersen J et al. Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. N Engl J Med 1992;327:1342–1349.
- Philip T, Guglielmi C, Haagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemother-apy in relapses of chemotherapy sensitive non-Hodgkin's lymphoma. N Engl J Med 1995;333:1540–1545.
- Kewalramani T, Zelenetz AD, Hedrick EE et al. High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis. Blood 2000;96:2399–2404.
- Vose JM. High-dose chemotherapy and hematopoietic stem cell transplantation for relapsed or refractory diffuse large-cell non-Hodgkin's lymphoma. Ann Oncol 1998;9 (Suppl. 1):S1–S3.
- Shipp MA, Abeloff MD, Antman KH et al. International Consensus Conference on High-dose Therapy with Hemato-poietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: report of the jury. J Chin Oncol 1999;17:423–429.
- Hamlin PA, Zelenetz AD, Kewalramani T et al. Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2003;102:1989–1996.
- Blay J, Gomez F, Sebban C et al. The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group. Blood 1998;92:3562–3568.
- The International Non-Hodgkin's Lymphoma Prognostic Factor Project: a predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993;329:987–994.
- Philip T, Armitage JO, Spitzer G et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med 1987;316:1493–1498.
- Vose JM, Zhang MJ, Rowlings PA et al. Autologous transplantation for diffuse aggressive non-Hodgkin's lympho-ma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Chin Oncol 2001;19:406–413.
- Stiff PJ, Dahlberg S, Forman SJ. Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: value of augmented preparative regimens - A Southwest Oncology Group Trial. J Chin Oncol 1998;16:48–55.
- Vose JM, Anderson JR, Kessinger A et al. High-dose chemotherapy and autologous hematopoietic stem-cell trans-plantation for aggressive non-Hodgkin's lymphoma. J Chin Oncol 1993;11:1846–1851.
- De Kreuk M, Ossenkoppele GJ, Meijer CJ et al. Prognostic factors for survival of non-Hodgkin's lymphoma patients treated with high-dose chemotherapy and autologous bone marrow transplantation. Bone Marrow Transplant 1996;17:963–971.